SecurityAKAO / Achaogen, Inc. (004449104)
IndustryPharmaceutical Preparations
Institutional Owners118
Institutional Shares32,045,678 - 71.54%
Common Shares Outstanding44,796,291 shares (as of 2018-03-31)
Institutional Value$ 17,239,310,000 USD

Institutional Stock Ownership and Shareholders

AKAO / Achaogen, Inc. Institutional Ownership

Achaogen, Inc. (NASDAQ:AKAO) has 118 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 32,045,678 shares. Largest shareholders include NEA Management Company, LLC, FMR LLC / Fidelity, State Street Corp, BlackRock Inc., Foresite Capital Management III, LLC, Vanguard Group Inc, TimesSquare Capital Management, LLC, Versant Venture Management, LLC, Price T Rowe Associates Inc /md/, and EverPoint Asset Management, LLC.
Achaogen, Inc. (NASDAQ:AKAO) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/akao"><img src="https://images.fintel.io/us-akao-so.png" alt="AKAO / Achaogen, Inc. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-01 13F-HR Stanley-Laman Group, Ltd. 69,889 0 -100.00 751 0 -100.00
2018-05-15 13F-HR Foresite Capital Management III, LLC Put 200,000 2,600
2018-05-14 13F-HR Renaissance Technologies LLC 642,700 423,800 -34.06 6,903 5,488 -20.50
2018-05-04 13F-HR Swiss National Bank 44,300 50,000 12.87 476 648 36.13
2017-02-14 13F-HR EverPoint Asset Management, LLC 675,000 8,789
2018-05-14 13F-HR Prosight Management, LP 570,920 661,054 15.79 6,132 8,561 39.61
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 128,313 102,305 -20.27 1,378 1,325 -3.85
2017-02-10 13F-HR BlackRock Fund Advisors 60,100 72,653 20.89 288 946 228.47
2017-08-08 13F-HR Airain ltd 31,507 685
2017-02-10 13F-HR BlackRock Japan Co. Ltd 0 829 0 11
2018-04-23 13F-HR Financial Architects, Inc 2,603 2,253 -13.45 28 29 3.57
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 103,851 430,796 314.82 497 5,609 1,028.57
2018-05-14 13F-HR RMB Capital Management, LLC 127,407 1,650
2018-05-10 13F-HR NEA Management Company, LLC 5,215,128 5,215,128 0.00 56,010 67,536 20.58
2018-05-15 13F-HR GOLDMAN SACHS GROUP INC 331,039 351,670 6.23 3,555 4,554 28.10
2018-02-09 13F-HR RidgeWorth Capital Management LLC 0 31,243 0 336
2018-04-26 13F-HR Ballentine Partners, LLC 19,823 19,823 0.00 213 257 20.66
2018-05-14 13F-HR/A CITADEL ADVISORS LLC Call 29,800 104,700 251.34 320 1,356 323.75
2018-05-15 13F-HR TWO SIGMA INVESTMENTS LLC 24,243 0 -100.00 260 0 -100.00
2018-05-03 13F-HR Zurcher Kantonalbank (Zurich Cantonalbank) 1,712 1,712 0.00 18 22 22.22
2018-05-15 13F-HR METROPOLITAN LIFE INSURANCE CO/NY 10,899 10,899 0.00 117 141,142 120,534.19
2018-05-15 13F-HR Metlife Investment Advisors, Llc 14,077 14,077 0.00 151 182 20.53
2018-04-17 13F-HR BENJAMIN F. EDWARDS & COMPANY, INC. 800 10
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 44,121 52,899 19.90 474 685 44.51
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Call 101,500 259,200 155.37 1,090 3,357 207.98
2018-05-08 13F-HR Marcus Capital, LLC 17,400 19,650 12.93 187 254 35.83
2018-05-07 13F-HR Engineers Gate Manager LP 38,395 97,817 154.76 412 1,267 207.52
2018-05-11 13F-HR TD ASSET MANAGEMENT INC 39,226 40,226 2.55 421 521 23.75
2018-05-11 13F-HR Winch Advisory Services, LLC 200 0 -100.00 2 0 -100.00
2018-05-11 13F-HR Fiera Capital Corp 181,164 165,457 -8.67 1,945 2,143 10.18
2018-05-14 13F-HR FMR LLC / Fidelity 5,027,293 3,764,966 -25.11 53,993 48,756 -9.70
2018-05-09 13F-HR GAMCO INVESTORS, INC. ET AL 66,200 857
2018-05-15 13F-HR UBS Group AG 38,086 297,632 681.47 409 3,854 842.30
2018-05-15 13F-HR Polar Capital LLP 1,881,380 0 -100.00 20,206 0 -100.00
2018-05-15 13F-HR Ameritas Investment Partners, Inc. 2,546 2,546 0.00 27 33 22.22
2018-05-15 13F-HR DEUTSCHE BANK AG\ 517,221 474,271 -8.30 5,553 6,140 10.57
2018-05-11 13F-HR CITADEL ADVISORS LLC Put 61,300 794
2018-05-15 13F-HR Schonfeld Strategic Advisors LLC 128,155 0 -100.00 1,377 0 -100.00
2018-04-26 13F-HR SIMPLEX TRADING, LLC 7,797 0 -100.00 83 0 -100.00
2018-05-10 13F-HR NEW YORK STATE COMMON RETIREMENT FUND 32,500 32,500 0.00 349 421 20.63
2018-05-09 13F-HR Candriam Luxembourg S.C.A. 172,555 222,555 28.98 1,853 2,882 55.53
2018-05-15 13F-HR JANE STREET GROUP, LLC 32,008 415
2018-05-14 13F-HR Pacer Advisors, Inc. 2,075 0 -100.00 22 0 -100.00
2018-05-11 13F-HR Cutler Group LP Call 3,400 1,700 -50.00 1 2 100.00
2018-05-08 13F-HR SIGNATUREFD, LLC 3 0
2018-05-09 13F-HR Teton Advisors, Inc. 33,000 427
2018-05-09 13F-HR BlackRock Inc. 2,837,846 2,898,459 2.14 30,478 37,536 23.16
2018-05-10 13F-HR FRED ALGER MANAGEMENT INC 5,000 65
2018-05-16 13F-HR/A GROUP ONE TRADING, L.P. Put 118,300 165,800 40.15 1,271 2,147 68.92
2018-05-15 13F-HR Bank of New York Mellon Corp 144,843 145,131 0.20 1,555 1,880 20.90
2018-05-14 13F-HR Axa 442,921 615,139 38.88 4,757 7,966 67.46
2018-05-09 13F-HR NORTHERN TRUST CORP 376,021 376,128 0.03 4,038 4,870 20.60
2018-05-15 13F-HR AQR CAPITAL MANAGEMENT LLC 26,041 0 -100.00 280 0 -100.00
2018-05-11 13F-HR SEI INVESTMENTS CO 88,000 0 -100.00 945 0 -100.00
2018-05-11 13F-HR Cutler Group LP Put 3,700 2,700 -27.03 6 2 -66.67
2018-05-15 13F-HR DSC Advisors, L.P. 70,000 0 -100.00 752 0 -100.00
2018-05-11 13F-HR CITADEL ADVISORS LLC Call 104,700 1,356
2018-05-14 13F-HR BOOTHBAY FUND MANAGEMENT, LLC 31,200 404
2018-05-15 13F-HR Wellington Management Group LLP 43,875 40,414 -7.89 471 524 11.25
2018-04-13 13F-HR BANK OF MONTREAL /CAN/ Put 9,000 29,000 222.22 97 376 287.63
2018-05-02 13F-HR RHUMBLINE ADVISERS 31,550 31,970 1.33 339 414 22.12
2018-05-15 13F-HR CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM 53,853 51,803 -3.81 578 671 16.09
2018-05-15 13F-HR Alyeska Investment Group, L.P. 300,000 198,214 -33.93 3,222 2,567 -20.33
2018-05-15 13F-HR DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main 31,122 403
2018-05-03 13F-HR Trexquant Investment LP 47,742 0 -100.00 513 0 -100.00
2018-05-15 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 26,721 26,722 0.00 287 346 20.56
2018-05-14 13F-HR ICONIQ Capital, LLC 28,629 28,629 0.00 307 371 20.85
2018-05-14 13F-HR MORGAN STANLEY 226,560 178,022 -21.42 2,433 2,305 -5.26
2018-05-14 13F-HR/A CITADEL ADVISORS LLC 32,005 0 -100.00 344 0 -100.00
2018-05-15 13F-HR BARCLAYS PLC 14,593 40,096 174.76 157 520 231.21
2018-05-11 13F-HR CITIGROUP INC 92,949 105,197 13.18 998 1,362 36.47
2018-05-10 13F-HR Artal Group S.A. 250,000 0 -100.00 2,685 0 -100.00
2018-05-15 13F-HR/A Sabby Management, LLC Call 713 923
2018-04-25 13F-HR FIRST MIDWEST BANK TRUST DIVISION 374,007 100,091 -73.24 4,017 1,296 -67.74
2018-05-14 13F-HR ProShare Advisors LLC 27,911 25,046 -10.26 300 324 8.00
2018-05-07 13F-HR STATE OF WISCONSIN INVESTMENT BOARD 22,000 22,000 0.00 236 285 20.76
2018-05-14 13F-HR Pacad Investment Ltd. 0 900 0 11
2018-05-04 13F-HR Granite Investment Partners, LLC 16,251 211
2018-05-15 13F-HR VANGUARD GROUP INC 1,546,004 1,524,986 -1.36 16,604 19,748 18.94
2018-05-01 13F-HR Clear Harbor Asset Management, LLC 16,511 14,710 -10.91 177 190 7.34
2018-05-09 13F-HR GABELLI FUNDS LLC 61,800 174,000 181.55 664 2,253 239.31
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 677 55 -91.88 8 0 -100.00
2018-04-18 13F-HR Creative Planning 0 71,160 0 922
2018-05-09 13F-HR IFP Advisors, Inc 219 219 0.00 2 3 50.00
2018-05-10 13F-HR JP Morgan Chase & Co 11,070 10,578 -4.44 119 137 15.13
2018-04-20 13F-HR Cable Hill Partners, LLC 800 2,000 150.00 9 24 166.67
2018-05-15 13F-HR HARBOURVEST PARTNERS LLC 20,000 20,000 0.00 215 259 20.47
2018-04-09 13F-HR CONTRAVISORY INVESTMENT MANAGEMENT, INC. 27 0 -100.00 0 0
2018-05-15 13F-HR BLAIR WILLIAM & CO/IL 0 43,129 0 559
2018-05-14 13F-HR AlpInvest Partners B.V. 21,886 283
2018-04-20 13F-HR Steward Partners Investment Advisory, Llc 7,650 11,675 52.61 82 151 84.15
2018-05-11 13F-HR STIFEL FINANCIAL CORP 10,391 134
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 294,718 303,152 2.86 3,165 3,925 24.01
2018-05-14 13F-HR Oz Management LP 49,400 194,900 294.53 531 2,524 375.33
2018-05-15 13F-HR Parallax Volatility Advisers, L.P. 5,308 0 -100.00 57 0 -100.00
2018-05-15 13F-HR Premier Asset Managment LLC 36,216 30,953 -14.53 389 401 3.08
2018-05-04 13F-HR STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM 16,696 16,696 0.00 179 216 20.67
2018-05-15 13F-HR Foresite Capital Management III, LLC 2,375,000 2,850,000 20.00 25,508 36,908 44.69
2018-05-14 13F-HR/A CITADEL ADVISORS LLC Put 58,700 61,300 4.43 630 794 26.03
2018-04-18 13F-HR Sonora Investment Management, LLC 1,000 1,000 0.00 10,740 12,950 20.58
2018-05-15 13F-HR International Biotechnology Trust Plc 204,538 0 -100.00 2,197 0 -100.00
2018-05-17 13F-HR Legal & General Group Plc 8,645 6,236 -27.87 93 80 -13.98
2018-05-14 13F-HR TIAA CREF INVESTMENT MANAGEMENT LLC 79,911 79,911 0.00 858 1,035 20.63
2018-05-14 13F-HR ALLIANCEBERNSTEIN L.P. 117,400 59,600 -49.23 1,261 772 -38.78
2018-05-07 13F-HR AMERICAN INTERNATIONAL GROUP INC 23,013 21,839 -5.10 247 283 14.57
2018-05-15 13F-HR CREDIT SUISSE AG/ 29,567 33,373 12.87 317 432 36.28
2018-05-14 13F-HR Oz Management LP Put 49,400 194,900 294.53 531 2,524 375.33
2018-05-15 13F-HR D. E. Shaw & Co., Inc. 39,847 516
2018-05-04 13F-HR SAN FRANCISCO SENTRY INVESTMENT GROUP (CA) 600 600 0.00 6 8 33.33
2018-05-15 13F-HR Voya Investment Management LLC 15,435 15,435 0.00 166 200 20.48
2018-05-15 13F-HR Weiss Multi-Strategy Advisers LLC 35,000 24,180 -30.91 376 313 -16.76
2018-05-15 13F-HR Tower Research Capital LLC (TRC) 18,648 754 -95.96 201 10 -95.02
2018-04-26 13F-HR SIMPLEX TRADING, LLC Put 362 53 -85.36 118 3 -97.46
2018-05-15 13F-HR BARCLAYS PLC Put 30,000 389
2018-05-14 13F-HR TEACHERS ADVISORS INC 62,483 76,794 22.90 671 994 48.14
2018-05-14 13F-HR INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC 200 3
2018-05-15 13F-HR ELLINGTON MANAGEMENT GROUP LLC 16,500 0 -100.00 177 0 -100.00
2018-05-15 13F-HR STATE STREET CORP 2,383,455 3,103,029 30.19 25,598 40,182 56.97
2018-05-15 13F-HR Iguana Healthcare Management, LLC 75,000 100,000 33.33 806 1,295 60.67
2018-05-15 13F-HR Point72 Asset Management, L.P. 1,502,400 0 -100.00 16,136 0 -100.00
2018-05-14 13F-HR PRICE T ROWE ASSOCIATES INC /MD/ 947,056 1,010,008 6.65 10,171 13,080 28.60
2018-05-15 13F-HR TimesSquare Capital Management, LLC 1,367,965 1,284,411 -6.11 14,692 16,633 13.21
2018-04-10 13F-HR CHESLEY TAFT & ASSOCIATES LLC/IL 18,075 234
2018-05-07 13F-HR SCHWAB CHARLES INVESTMENT MANAGEMENT INC 137,716 160,830 16.78 1,480 2,083 40.74
2018-05-16 13F-HR/A GROUP ONE TRADING, L.P. Call 5,300 89,500 1,588.68 57 1,159 1,933.33
2018-05-23 13F-HR/A Allianz Asset Management AG 51,035 92,781 81.80 548 1,202 119.34
2018-05-03 13F-HR DekaBank Deutsche Girozentrale 16,500 207
2018-04-18 13F-HR REGIONS FINANCIAL CORP 4,500 0 -100.00 48 0 -100.00
2018-05-08 13F-HR US BANCORP \DE\ 6,119 4,809 -21.41 66 62 -6.06
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Put 188,800 365,000 93.33 2,028 4,727 133.09
2018-05-15 13F-HR Point72 Asset Management, L.P. Put 205,000 2,655
2018-05-14 13F-HR Hikari Power Ltd 60,000 60,000 0.00 644 777 20.65
2018-05-15 13F-HR Baker Brothers Advisors LP 122,482 0 -100.00 1,315 0 -100.00
2017-02-10 13F-HR BlackRock Group LTD 38,834 22,304 -42.57 186 290 55.91
2018-05-15 13F-HR/A Sabby Management, LLC Put 1,405 1,819
2018-04-16 13F-HR Raymond James Financial Services Advisors, Inc. 103,340 93,190 -9.82 1,110 1,207 8.74
2018-04-18 13F-HR/A FNY Managed Accounts LLC Call 4 0
2018-05-15 13F-HR Quantitative Investment Management, LLC 133,500 93,700 -29.81 1,433 1,213 -15.35
2018-05-11 13F-HR Cutler Group LP 1,400 1,000 -28.57 15 12 -20.00
2018-04-10 13F-HR Gierl Augustine Investment Management Inc 1,000 1,000 0.00 11 13 18.18
2018-05-01 13F-HR WEDBUSH SECURITIES INC 25,050 324
2018-05-15 13F-HR LORD, ABBETT & CO. LLC 366,247 365,203 -0.29 3,933 4,730 20.26
2018-05-16 13F-HR/A GROUP ONE TRADING, L.P. 94,980 61,663 -35.08 1,020 799 -21.67
2018-05-03 13F-HR Versant Venture Management, LLC 1,281,152 1,281,152 0.00 13,759,572 16,590,918 20.58
2018-05-10 13F-HR GREAT WEST LIFE ASSURANCE CO /CAN/ 2,200 2,200 0.00 24 29 20.83
2017-01-13 13F-HR MetLife Securities, Inc 1,000 13
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 50,683 52,901 4.38 545 685 25.69
2018-04-16 13F-HR Raymond James Financial Services Advisors, Inc. Put 36,100 31,900 -11.63 357 242 -32.21
2018-05-02 13F-HR Daiwa Securities Group Inc. 234 3
2017-02-13 SC 13G/A ARCH VENTURE FUND VI LP 1,418,657
2018-05-11 13F-HR BNP PARIBAS ARBITRAGE, SA 7,287 7,403 1.59 78,262 95,869 22.50
2018-05-15 13F-HR Squarepoint Ops LLC 28,487 0 -100.00 306 0 -100.00
2017-02-10 13F-HR BlackRock Investment Management, LLC 3,744 3,744 0.00 18 49 172.22
2018-04-13 13F-HR BANK OF MONTREAL /CAN/ 21,000 31,000 47.62 225 402 78.67
2018-05-17 13F-HR Atlantic Trust Group, LLC 12 0
AKAO : Achaogen Stock Analysis and Research Report

2017-11-08 - Asif

Achaogen is a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterial treatments against multi-drug resistant (“MDR”) gram-negative infections. Achaogen is researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (“cUTI”), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (“CRE”). In 2013, the Centers for Disease Control and Prevention identified CRE as a “nightmare bacteria” and an immediate public health threat that requires “urgent and aggressive action” and in 2017 the World Health Organization identified CRE as a Global Priority 1 Pathogen: Critical Need for Research and Development of New Antibiotics. On December 12, 2016, the company announced positive data from its two Phase 3 clinical trials for plazomicin. The firs...

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

10h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Related News Stories

Rounds Report: Ocular Rallied While Stellar FDA Due Diligence To Help Antibiotic Innovators

2018-06-13 seekingalpha
The overall bioscience market traded on an uptrend for the day. Many firms under our coverage continued to post further gains. (139-2)

Biopharma Companies to Watch This Week and for the Rest of June

2018-06-09 247wallst
Companies in the biotech and pharmaceutical industries are subject to a sizable amount of risk with regards to their drug candidates passing clinical trials and gaining regulatory approval. But with the risk of failure, which could spell disaster for a stock, comes great reward as well. Some companies can see a massive upside just from winning a single midstage trial or even achieving as much as a Fast Track designation from the U. (116-2)

Integrated BioSci Research On Cidara Therapeutics: What's In Store For This Promising Antibiotic Innovator?

2018-06-08 seekingalpha
Wall Street has not been favoring infectious disease innovators. Nevertheless, the fundamentals of those firms are quite robust and are improving. (98-5)

Rounds Report: Melinta Rallied While Novavax Experienced Significant Insider Purchases

2018-06-06 seekingalpha
The bioscience market traded slightly south with an overall skittish sentiment. Despite some key losers, many equities under our coverage continued to break the trend to post further gains. (228-2)

Key FDA Events in June Investors Need to Watch Out For

2018-06-01 zacks
It has been a busy year for the FDA so far with the agency approving 14 drugs. Key approvals include Novartis’ Lutathera, Gilead Sciences’ HIV regimen, Biktarvy; Vertex Pharmaceuticals’ Symdeko (tezacaftor/ivacaftor and ivacaftor) for the treatment of cystic fibrosis (CF), Johnson & Johnson’s Erleada for prostate cancer, Amgen’s Aimoviq for the treatment of migraine, BioMarin’s Palynziq for the treatment of phenylketonuria, and Dova Pharmaceuticals Doptelet among others. (326-4)

CUSIP: 004449104